Leflunomida Pentafarma

Leflunomide, the active ingredient in Leflunomida Pentafarma, is an immunomodulatory (dihydroorotate dehydrogenase inhibitor) presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunomida Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that targets inflammatory arthritis pathways. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Active inflammatory arthritis: helps control disease activity when conventional therapy is insufficient.

Leflunomida Pentafarma may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Elevated liver enzymes: transient increase in ALT/AST. - Hypertension: new‑onset or worsening blood pressure. - Rash: non‑specific skin eruptions.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: neutropenia, anemia, or thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or pneumonitis.

Before initiating therapy, clinicians should evaluate baseline safety parameters and monitor patients regularly. - Liver monitoring: check ALT/AST before start and periodically during treatment. - Hematology checks: perform complete blood count at baseline and during therapy. - Pregnancy avoidance: use effective contraception; discontinue if pregnancy occurs. - Vaccination guidance: avoid live vaccines while on treatment. - Drug‑induced hypertension: monitor blood pressure and manage as needed. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: additive hepatotoxicity and bone‑marrow suppression. - Teriflunomide: overlapping toxicity, especially hepatic.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin): higher risk of myopathy. - Oral contraceptives: reduced efficacy, consider alternative methods. - Azathioprine: enhanced immunosuppression, monitor blood counts.